Just because a business does not make any money, does not mean that the stock will go down. Indeed, NeuroMetrix (NASDAQ:NURO) stock is up 920% in the last year, providing strong gains for shareholders ...
Some NeuroMetrix, Inc. (NASDAQ:NURO) shareholders are probably rather concerned to see the share price fall 55% over the last three months. But that cannot eclipse the spectacular share price rise ...
WOBURN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (“NeuroMetrix” or the“Company”) (Nasdaq: NURO) today announced it has entered into a ...
On December 2, Bradley Fluegel notified the Board of Directors of NeuroMetrix (NURO), of his decision to resign from the Board and as a member of the Board’s Audit Committee, effective as of December ...
The NeuroMetrix team has proven that it can successfully commercialize medical device products through its highly capable team, including its sales force. I personally look forward to carrying out the ...
electroCore (ECOR) announced it has entered into a definitive agreement to acquire NeuroMetrix (NURO), including its Quell platform. The transaction does not include the DPNCheck technology and ...
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NAS: NURO) , a medical device company focused on the treatment and management of chronic pain, peripheral neuropathies, and related neurological ...
WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) today reported that Michael MacDonald has been promoted to SVP and General Manager of Diagnostics. In this role, Mr. MacDonald will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback